{
  "id": 17930783,
  "title": "Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial",
  "url": "https://urgent.news/2026/11/03/chinese-drug-iza-bren-doubles-lung-cancer-survival-window-in-phase-3",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-03T08:00:09.000Z",
  "source": {
    "name": "Reuters Business via SCMP",
    "slug": "reuters-business-via-scmp",
    "url": "https://www.scmp.com/news/china/science/article/3373061/chinese-drug-iza-bren-doubles-lung-cancer-survival-window-phase-3-trial"
  },
  "original_language": "en",
  "account": "The anticancer drug iza-bren, developed by Sichuan Biokin Pharmaceutical, demonstrated a significant improvement in lung cancer survival rates in a phase 3 clinical trial conducted in China. Published online by The Lancet, the study involved 432 patients with advanced lung cancer and found that iza-bren doubled the median progression-free survival time compared to platinum-based chemotherapy. While iza-bren showed a higher incidence of adverse reactions, mainly affecting blood cell counts, no new safety concerns were identified. iza-bren is a first-in-class bispecific antibody-drug conjugate that targets two tumor-associated antigens, EGFR and HER3, and is the world's first approved bispecific ADC. The drug has already been approved for two indications in China and has marketing applications under review for lung cancer and two types of breast cancer. China has become a leading global hub for clinical trial registrations and early-stage drug development, with a growing number of patients seeking access to innovative therapies like iza-bren.",
  "summary": "An anticancer drug developed by Sichuan Biokin Pharmaceutical took centre stage in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress in Madrid last week. Researchers said the drug, iza-bren, showed a significant advantage over platinum-based chemotherapy in a phase 3 randomised, double-blind clinical trial conducted at 73 hospitals in China and…",
  "key_points": [
    "Iza-bren doubled median progression-free survival in lung cancer patients",
    "Phase 3 trial involved 432 advanced lung cancer patients",
    "Iza-bren is first approved bispecific ADC worldwide"
  ],
  "editors_take": "The success of this first-in-class bispecific antibody-drug conjugate reinforces China's growing role as a global leader in early-stage drug development and the delivery of innovative cancer therapies.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}